In case you missed it: March 22 to March 26

Article

It's been a very busy week for the Contemporary OB/GYN team.

This week's top articles included:

Nextstellis combined oral contraceptive and endocrine markers

Limited changes occur in endocrine markers with the combined oral contraceptive Nextstellis (Mayne Pharma), according to a prospective study presented at the virtual annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) in March.

Hominis surgical robot receives De Novo marketing authorization

The privately held medical device firm Memic Innovative Surgery Ltd. announced in early March that the Food and Drug Administration (FDA) has granted De Novo marketing authorization for its Hominis, a robot-assisted surgical platform for use in single site, natural orifice laparoscopic-assisted transvaginal benign gynecologic procedures, including benign hysterectomy.

Time Sensitive: Sign up soon to participate in Expert Panel

Panel will be focused on early detection, screening, and treatment of ovarian cancer.

Related Videos
Fezolinetant effective against vasomotor symptoms | Image Credit: med.unc.edu
Discussing PCOS: misconceptions, management, encouragement | Image Credit: ahn.org
The importance of diversity in obstetrics | Image Credit: © stanfordchildrens.org
Study confirms efficacy of JADA against postpartum bleeding | Image Credit: © Amy Taneja MD - © Amy Taneja MD - linkedin.com.
Matthew Zerden, MD
John Stanley, MD
Marci Bowers, MD | Image Credit: Marcibowers.com
© 2023 MJH Life Sciences

All rights reserved.